Nkarta Receives NKX019 IND Clearance from U.S. Food and Drug Administration for Treatment of Relapsed/Refractory B Cell MalignanciesGlobeNewsWire • 04/28/21
Nkarta Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Business ProgressGlobeNewsWire • 03/25/21
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101GlobeNewsWire • 11/12/20
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of CancerGlobeNewsWire • 11/09/20
Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 07/14/20